{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:21:32Z","timestamp":1768983692024,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03827-4","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T17:42:27Z","timestamp":1735580547000},"page":"3223-3231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct02101684","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-3601","authenticated-orcid":false,"given":"Jesus","family":"Garcia-Donas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Garrigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Lainez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Santaballa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Fernando","family":"Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Jesus","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Antonio","family":"Lopez-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaida","family":"Garcia-Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aranzanzu","family":"Barquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Guerra","family":"Alia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sevillano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Bover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana P","family":"Grazioso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Sanchez-Escribano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Francisco","family":"Rodriguez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"3827_CR1","unstructured":"Kurman RJ, Carcangiu ML, Herrington S, et al. WHO classification of tumours of female reproductive organs.4th Edition, Volume 6 Int Agency Res Cancer. 2014."},{"key":"3827_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.critrevonc.2017.10.007","volume":"120","author":"S Boussios","year":"2017","unstructured":"Boussios S, Moschetta M, Zarkavelis G, Papadaki A, Kefas A, Tatsi K. Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects. Crit Rev Oncol Hematol [Internet]. 2017;120:43\u201351.","journal-title":"Crit Rev Oncol Hematol [Internet]"},{"issue":"26","key":"3827_CR3","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1056\/NEJMoa0902542","volume":"360","author":"SP Shah","year":"2009","unstructured":"Shah SP, K\u00f6bel M, Senz J, Morin RD, Clarke BA, Wiegand KC, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med [Internet]. 2009;360(26):2719\u201329. https:\/\/doi.org\/10.1056\/NEJMoa0902542.","journal-title":"N Engl J Med [Internet]"},{"key":"3827_CR4","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdy001","volume":"29","author":"I Ray-Coquard","year":"2018","unstructured":"Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2018;29:iv1\u201318.","journal-title":"Ann Oncol [Internet]."},{"issue":"27","key":"3827_CR5","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/JCO.18.02419","volume":"37","author":"DM Gershenson","year":"2019","unstructured":"Gershenson DM, Okamoto A, Ray-Coquard I. Management of rare ovarian cancer histologies. J Clin Oncol [Internet]. 2019;37(27):2406\u201315. https:\/\/doi.org\/10.1200\/JCO.18.02419.","journal-title":"J Clin Oncol [Internet]"},{"issue":"3","key":"3827_CR6","doi-asserted-by":"publisher","first-page":"1106-","DOI":"10.3390\/ijerph19031106","volume":"19","author":"A Cheung","year":"2022","unstructured":"Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M, et al. Non-epithelial ovarian cancers: how much do we really know? Int J Environ Res Public Health. 2022;19(3):1106-1124","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"3827_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1159\/000515412","volume":"15","author":"M Ohta","year":"2021","unstructured":"Ohta M, Hara Y, Kashiwadate T, Chin M, Hagiwara M, Nakanishi W, et al. Recurrence of adult granulosa cell tumor in the greater omentum 11 years after surgery. Case Rep Gastroenterol [Internet]. 2021;15(2):639\u201344. https:\/\/doi.org\/10.1159\/000515412.","journal-title":"Case Rep Gastroenterol [Internet]"},{"key":"3827_CR8","doi-asserted-by":"crossref","unstructured":"Saani I, Raj N, Sood R, Ansari S, Mandviwala HA, Sanchez E, et al. Clinical challenges in the management of malignant ovarian germ cell tumours. Int J Environ Res Public Health [Internet]. 2023;20(12):6089. https:\/\/www.mdpi.com\/1660-4601\/20\/12\/6089.","DOI":"10.3390\/ijerph20126089"},{"issue":"2","key":"3827_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1006\/gyno.1998.5304","volume":"72","author":"HD Homesley","year":"1999","unstructured":"Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a gynecologic oncology group study. Gynecol Oncol [Internet]. 1999;72(2):131\u20137.","journal-title":"Gynecol Oncol [Internet]"},{"issue":"9","key":"3827_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0959-8049(99)00142-2","volume":"35","author":"S Pecorelli","year":"1999","unstructured":"Pecorelli S, Wagenaar H, Vergote I, Curran D, Beex LV, Wiltshaw E, et al. Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC gynaecological cancer cooperative group study. Eur J Cancer [Internet]. 1999;35(9):1331\u20137.","journal-title":"Eur J Cancer [Internet]."},{"issue":"1","key":"3827_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ygyno.2015.11.027","volume":"140","author":"ER Burton","year":"2016","unstructured":"Burton ER, Brady M, Homesley HD, Rose PG, Nakamura T, Kesterson JP, et al. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: an NRG Oncology\/Gynecologic Oncology Group Study. Gynecol Oncol [Internet]. 2016;140(1):48\u201352.","journal-title":"Gynecol Oncol [Internet]"},{"issue":"3","key":"3827_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/cncr.28421","volume":"120","author":"J Brown","year":"2014","unstructured":"Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer [Internet]. 2014;120(3):344\u201351. https:\/\/doi.org\/10.1002\/cncr.28421.","journal-title":"Cancer [Internet]"},{"key":"3827_CR13","doi-asserted-by":"crossref","unstructured":"Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, Fujiwara K, et al. Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors. JAMA Oncol [Internet]. 2020;6(12):1923. https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2771198.","DOI":"10.1001\/jamaoncol.2020.4574"},{"key":"3827_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.biocel.2016.01.003","volume":"72","author":"DTH Leung","year":"2016","unstructured":"Leung DTH, Fuller PJ, Chu S. Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors. Int J Biochem Cell Biol [Internet]. 2016;72:51\u20134.","journal-title":"Int J Biochem Cell Biol [Internet]"},{"key":"3827_CR15","first-page":"236","volume":"13","author":"A Fishman","year":"1994","unstructured":"Fishman A, Kudelka AEC, et al. GnRH (Depot-Lupron) in the treatment of refractory or persistent ovarian granulosa cell tumors (GCT). Proc Am Soc Clin Oncol. 1994;13:236.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"3827_CR16","doi-asserted-by":"crossref","unstructured":"Isaacs R, Forgeson G, Allan S. Progestagens for granulosa cell tumours of the ovary. Br J Cancer [Internet]. 1992;65(1):140\u2013140. https:\/\/www.nature.com\/articles\/bjc199228.","DOI":"10.1038\/bjc.1992.28"},{"key":"3827_CR17","doi-asserted-by":"crossref","unstructured":"Malik S, Slevin M. Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary\u2014a new therapeutic approach? Br J Cancer [Internet]. 1991;63(3):410\u20131. https:\/\/www.nature.com\/articles\/bjc199194.","DOI":"10.1038\/bjc.1991.94"},{"issue":"3","key":"3827_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/0090-8258(89)90089-9","volume":"35","author":"H Martikainen","year":"1989","unstructured":"Martikainen H, Penttinen J, Huhtaniemi I, Kauppila A. Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy. Gynecol Oncol [Internet]. 1989;35(3):406\u20138.","journal-title":"Gynecol Oncol [Internet]"},{"issue":"3","key":"3827_CR19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ygyno.2004.10.042","volume":"96","author":"RD Hardy","year":"2005","unstructured":"Hardy RD, Bell JG, Nicely CJ, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol [Internet]. 2005;96(3):865\u20139.","journal-title":"Gynecol Oncol [Internet]"},{"key":"3827_CR20","unstructured":"Fishman A, Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Kaplan AL, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med [Internet]. 1996;41(6):393\u20136. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8799913."},{"key":"3827_CR21","doi-asserted-by":"crossref","unstructured":"Banerjee SN, Tang M, O\u2019Connell RL, Sjoquist K, Clamp AR, Millan D, et al. A phase 2 study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: the PARAGON\/ANZGOG 0903 trial. Gynecol Oncol [Internet]. 2021;163(1):72\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34412908.","DOI":"10.1016\/j.ygyno.2021.07.024"},{"key":"3827_CR22","doi-asserted-by":"crossref","unstructured":"Park M, Shin E, Won M, Kim JH, Go H, Kim HL, et al. FOXL2 interacts with steroidogenic factor-1 (SF-1) and represses SF-1-induced CYP17 transcription in granulosa cells. Mol Endocrinol [Internet]. 2010;24(5):1024\u201336. https:\/\/academic.oup.com\/mend\/article\/24\/5\/1024\/2706165.","DOI":"10.1210\/me.2009-0375"},{"issue":"10","key":"3827_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/JCO.2012.45.0346","volume":"31","author":"J Garcia-Donas","year":"2013","unstructured":"Garcia-Donas J, Hurtado A, Garc\u00eda-Casado Z, Albareda J, L\u00f3pez-Guerrero JA, Alemany I, et al. Cytochrome P17 inhibition with ketoconazole as treatment for advanced granulosa cell ovarian tumor. J Clin Oncol. 2013;31(10):165\u20136.","journal-title":"J Clin Oncol"},{"key":"3827_CR24","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01584297. Accessed 30 Oct 2022."},{"issue":"28","key":"3827_CR25","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1200\/JCO.21.02517","volume":"40","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, et al. Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216). J Clin Oncol [Internet]. 2022;40(28):3301\u20139. https:\/\/doi.org\/10.1200\/JCO.21.02517.","journal-title":"J Clin Oncol [Internet]"},{"issue":"1","key":"3827_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12967-021-02754-0","volume":"19","author":"C Secchi","year":"2021","unstructured":"Secchi C, Benaglio P, Mulas F, Belli M, Stupack D, Shimasaki S. FOXO1 mitigates the SMAD3\/FOXL2C134W transcriptomic effect in a model of human adult granulosa cell tumor. J Transl Med [Internet]. 2021;19(1):90. https:\/\/doi.org\/10.1186\/s12967-021-02754-0.","journal-title":"J Transl Med [Internet]"},{"issue":"3","key":"3827_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cjp2.198","volume":"7","author":"JA Pilsworth","year":"2021","unstructured":"Pilsworth JA, Cochrane DR, Neilson SJ, Moussavi BH, Lai D, Munzur AD, et al. Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. J Pathol Clin Res [Internet]. 2021;7(3):243\u201352. https:\/\/doi.org\/10.1002\/cjp2.198.","journal-title":"J Pathol Clin Res [Internet]"},{"key":"3827_CR28","doi-asserted-by":"crossref","unstructured":"Hillman RT, Lin DI, Lawson B, Gershenson DM. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol [Internet]. 2021;162(3):728\u201334. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34238613.","DOI":"10.1016\/j.ygyno.2021.06.024"},{"key":"3827_CR29","doi-asserted-by":"crossref","unstructured":"Andersson N, Haltia UM, F\u00e4rkkil\u00e4 A, Wong SC, Eloranta K, Wilson DB, et al. Analysis of non-relapsed and relapsed adult type granulosa cell tumors suggests stable transcriptomes during tumor progression. Curr Issues Mol Biol [Internet]. 2022;44(2):686\u201398. https:\/\/www.mdpi.com\/1467-3045\/44\/2\/48.","DOI":"10.3390\/cimb44020048"},{"issue":"3","key":"3827_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/path.5843","volume":"256","author":"V Cluzet","year":"2022","unstructured":"Cluzet V, Devillers MM, Petit F, Pierre A, Giton F, Airaud E, et al. Estradiol promotes cell survival and induces Greb expression in granulosa cell tumors of the ovary through an ER\u03b1-dependent mechanism. J Pathol [Internet]. 2022;256(3):335\u201348. https:\/\/doi.org\/10.1002\/path.5843.","journal-title":"J Pathol [Internet]"},{"issue":"3","key":"3827_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/ijgc-2018-000065","volume":"29","author":"AM Mills","year":"2019","unstructured":"Mills AM, Chinn Z, Rauh LA, Dusenbery AC, Whitehair RM, Saks E, et al. Emerging biomarkers in ovarian granulosa cell tumors. Int J Gynecol Cancer [Internet]. 2019;29(3):560\u20135. https:\/\/doi.org\/10.1136\/ijgc-2018-000065.","journal-title":"Int J Gynecol Cancer [Internet]"},{"issue":"1","key":"3827_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ygyno.2018.05.013","volume":"150","author":"A Ciucci","year":"2018","unstructured":"Ciucci A, Ferrandina G, Mascilini F, Filippetti F, Scambia G, Zannoni GF, et al. Estrogen receptor \u03b2: Potential target for therapy in adult granulosa cell tumors? Gynecol Oncol [Internet]. 2018;150(1):158\u201365.","journal-title":"Gynecol Oncol [Internet]"},{"issue":"12","key":"3827_CR33","doi-asserted-by":"publisher","first-page":"e14389","DOI":"10.1371\/journal.pone.0014389","volume":"5","author":"NI Fleming","year":"2010","unstructured":"Fleming NI, Knower KC, Lazarus KA, Fuller PJ, Simpson ER, Clyne CD. Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. Dey SK, editor. PLoS One [Internet]. 2010;5(12):e14389. https:\/\/doi.org\/10.1371\/journal.pone.0014389.","journal-title":"PLoS One [Internet]."},{"issue":"1","key":"3827_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ygyno.2021.07.024","volume":"163","author":"SN Banerjee","year":"2021","unstructured":"Banerjee SN, Tang M, O\u2019Connell RL, Sjoquist K, Clamp AR, Millan D, et al. A phase 2 study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: The PARAGON\/ANZGOG 0903 trial. Gynecol Oncol [Internet]. 2021;163(1):72\u20138.","journal-title":"Gynecol Oncol [Internet]"},{"key":"3827_CR35","doi-asserted-by":"crossref","unstructured":"van Meurs HS, van Lonkhuijzen LRCW, Limpens J, van der Velden J, Buist MR. Hormone therapy in ovarian granulosa cell tumors: a systematic review. Gynecol Oncol [Internet]. 2014;134(1):196\u2013205. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24713548.","DOI":"10.1016\/j.ygyno.2014.03.573"},{"issue":"7","key":"3827_CR36","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.2014.56.5119","volume":"33","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy. J Clin Oncol [Internet]. 2015;33(7):723\u201331. https:\/\/doi.org\/10.1200\/JCO.2014.56.5119.","journal-title":"J Clin Oncol [Internet]."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03827-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03827-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03827-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:35:11Z","timestamp":1750343711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03827-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["3827"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03827-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jesus Garcia-Donas, corresponding author, has received research funding from Gilead Inc, Pfizer Inc, Merck Inc, Bristol-Myers Squibb, AstraZeneca, Novartis, MSD Inc, Roche Inc, Astellas Inc, Novartis Inc, and Exelixis Inc. He has acted as a speaker for Gilead Inc, Pfizer Inc, Merck Inc, Bristol-Myers Squibb, AstraZeneca, Novartis, Glaxo Smithkline Inc, and MSD Inc. He has served as a scientific advisor for Pfizer Inc, Merck Inc, Bristol-Myers Squibb, AstraZeneca, Novartis, and MSD Inc. Enrique Grande has received honoraria for speaker engagements, advisory roles or funding of continuous medical education from Adacap, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, and Thermo Fisher Scientific. EG has received research grants from Pfizer, Astra Zeneca, Astellas, and Lexicon Pharmaceuticals. AR has received honoraria for speaker engagements, advisory roles or funding of continuous medical education from Astellas, Bristol Myers Squibb, IPSEN, Pfizer, and MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided informed consent prior to their participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}